
    
      Study participants will receive a booster vaccination of DTaP-HB-PRP~T or Tritanrix-HepB/Hib™
      either concomitantly with Oral Polio Vaccine (OPV) following the completion of a three dose
      primary series with DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™, both given
      concomitantly with OPV. Participants will receive a booster dose of the vaccine they had
      received in the primary series, and a concomitant dose of OPV Study AL203 (NCT00343889).
    
  